Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03825367 |
Recruitment Status :
Active, not recruiting
First Posted : January 31, 2019
Last Update Posted : October 12, 2022
|
Sponsor:
Therapeutic Advances in Childhood Leukemia Consortium
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Therapeutic Advances in Childhood Leukemia Consortium
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | May 31, 2023 |
Estimated Study Completion Date : | March 30, 2024 |